Varifarma signs an exclusive distribution and license agreement with ADIENNE Pharma & Biotech for TEPADINA® in Argentina and Chile.
Buenos Aires (Argentina) September 20th, 2021 – Laboratorio Varifarma SA, a company focused on complex therapies and orphan diseases, and devoted to increasing the life expectancy of the patient announce they have signed an exclusive distribution and licensing agreement for TEPADINA® in Argentina and Chile with ADIENNE Pharma&Biotech, an integrated biopharmaceutical group of companies based in Lugano (Switzerland) which aims to develop a range of product candidates for orphan diseases for which existing treatment options are limited, the patient population is small and the clinical needs for therapies is high. TEPADINA® is an alkylating agent used with other medicines in the conditioning regimen before hematopoietic stem cell transplantation. Conditioning is a fundamental preparatory step for engrafting hematopoietic stem cell transplants in the patient’s marrow space and for controlling or eradicating the underlying disease. Bone marrow transplant, also called a stem cell transplant, is a procedure that infuses healthy cells, called stem cells, into a body to replace damaged or diseased bone marrow. Bone marrow transplants may use cells from your own body (autologous trans-plant) or from a donor (allogeneic transplant). TEPADINA® can be used for both transplantations, autologous and allogeneic. Lic. Marcelo Conti, Laboratorio Varifarma Director, commented: “At Varifarma we are very proud to be able to provide such an advanced medicine not only to Argentinian patients but also to other Latin American countries. We will be working with the same commitment and values that led us here as so to honor our alliance with ADIENNE and to accomplish our common goal which is providing patients with rare and severe diseases with innovative solutions”. Dr. Antonio Francesco Di Naro, Founder, Owner and President of ADIENNE, said: “We are very pleased to have established this collaboration with Varifarma, whose established track record of successful marketing of complex oncology and specialty products makes us confident that they are the best partner for our TEPADINA® product. Varifarma has a remarkable commercial team and infrastructure in place and we are highly confident in their ability to successfully leverage that platform with us.”
1
About TEPADINA® TEPADINA® is approved in several countries in the world including EU and USA. It has attained a key role in many conditioning regimens before autologous and allogeneic HSCT for treating myeloma, lymphomas, acute leukemia and other malignant and non-malignant hematological diseases as well as for the treatment of solid tumors, in adult and pediatric patients. For additional information please see the: www.adienne.com About Varifarma Focused on complex therapies and orphan diseases, Varifarma is a company which is devoted to increasing the life expectancy of the patient. Is our continuous commitment with innovation and the search of new effective therapies what has placed us as market reference in the oncology, hematology, hemophilia, transplant, and rare diseases divisions. We are renowned for our product’s high quality and our sustained commitment with the medical and scientific community. For over two decades, we have counted on distinguished professionals who have actively contributed to the search for the best solutions for patients, as well as for new challenges. Our mission inspires a strategy focused on moving towards new therapies, consolidating a portfolio of cutting-edge medicines.
About ADIENNE ADIENNE Pharma & Biotech is a bio-pharmaceutical company founded in 2004, dedicated to the treatment of rare and severe diseases, operating in worldwide pharmaceutical market. The headquarter is based in Lugano (Switzerland). The company is mainly focused, from the research to commercialization, on the fields of onco-hematology, autoimmune diseases, bone marrow and solid organ transplantation. ADIENNE’s product portfolio includes name patient-based products (NBP) and owned licensed medicinal products.
2
For more information:
Varifarma Luciana Conti Group Head of Communication Buenos Aires, Argentina Tel: (54 11) 4723-2830 lconti@varifarma.com.ar
For more information, please visit www.varifarma.com and follow us on: Facebook:
https://www.facebook.com/LaboratorioVarifarma
Linkedin:
https://www.linkedin.com/company/laboratorio-varifarma
Twitter:
https://twitter.com/varifarma
ADIENNE Andrea Di Naro Public Relations Department Tel: +41 912.104.726 pr@adienne.com
More information on www.adienne.com LinkedIn:
https://it.linkedin.com/company/adienne-italy.
3